Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals Ltd. has strengthened its financial position by receiving a $6.3 million R&D Tax Incentive refund from the Australian Government for the 2024 financial year. This boosts the company’s cash reserves to approximately $31 million, supporting its ongoing Phase 3 clinical trials for osteoarthritis, and highlights its commitment to advancing therapies for unmet medical needs.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health by discovering, developing, and delivering pharmaceutical therapies. The company primarily develops injectable pentosan polysulfate sodium (iPPS) for treating diseases with significant inflammation, such as osteoarthritis and mucopolysaccharidosis.
YTD Price Performance: 6.30%
Average Trading Volume: 7,936
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $110.9M
For a thorough assessment of PAR stock, go to TipRanks’ Stock Analysis page.
